31 results about "Demethylating agent" patented technology

Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.

The present application discloses a method for discovering a methylation marker gene for the conversion of a cell comprising: (i) comparing converted and unconverted cell gene expression content to identify a gene that is present in greater abundance in the unconverted cell; (ii) treating a converted cell with a demethylating agent and comparing its gene expression content with gene expression content of an untreated converted cell to identify a gene that is present in greater abundance in the cell treated with the demethylating agent; and (iii) identifying a gene that is common to the identified genes in steps (i) and (ii), wherein the common identified gene is the methylation marker gene.

The invention concerns compositions comprising a demethylationg agent and an antigen for inducing and enhancing antigen-specific immunity and uses thereof. The invention also concerns methods for enhancing antigen-specific immunity by administrating a demethylating agent.

Provided herein are pharmaceutical compositions and methods for treating disorders characterized by reduced expression of anti-oxidative stress enzymes in a subject. In one aspect, the present invention provides a method for inducing expression of anti-oxidative stress enzymes in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of a demethylating agent. The demethylating agent includes a phytochemical that induces expression of Nrf2 and Nrf2-mediated genes expressing anti-oxidative stress. Such phytochemicals include indoles, such as 3,3′-diindolylmethane (DIM) and indole-3-carbinol (I3C), and isothiocyanates, such as phenethyl isothiocyanate (PEITC) and sulforaphane (SFN).

The invention describes a pharmaceutical composition comprising at least compound selected from the group of demethylating agents and HDAC inhibitors and at least one somatostatin analog or dopamine agonist for the treatment of a tumor which expresses a somatostatin and/or dopamine receptor.

Disclosed herein is a three-component gene expression reporting system for mammalian cells, the system including a first expression cassette, a second expression cassette, and a methylated polynucleotide. The three-component gene expression reporting system can be used to establish recombinant mammalian cells for use in the screening of a demethylating agent.

Desvenlafaxine is formed from venlafaxine by the use of a demethylating agent comprising a metal sulfide, such as sodium sulfide, and optionally selenium.

Provided are methods and compositions for treating cancers in patients carrying an IDHl mutation using a combination of an inhibitor of a mutant IDHl enzyme and a DNA demethylating agent.

The invention describs a method of producing cells for transplantation into myocardial tissue of a mammal. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) passage culturing two times said bone marrow stem cells under conditions that maintain the characteristics of bone marrow stem cells; (c) culturing said bone marrow stem cells in cardiac specific media to differentiate into cardiomyogenic cells; and (d) collecting the cells of step (c) when about 80 to 90% of said cells are cardiomyogenic cells. The cardiomyogenic cells induced according to the method can be clinically applied more suitably than those induced using demethylating agent such as 5-azacytidine, and therefore, they provide induced bone marrow stem cells of a mammal into cardiomyocytes having high rates of cell incorporation and cell survival for treating a mammal (e.g., a human) diagnosed as having a disorder characterized by insufficient cardiac function.

The present invention includes methods diagnosising of cancer by analysis of a patient sample, particularly for the presence of a methylated SPARC nucleic acid molecule, and particularly for the diagnosis of pancreatic cancer. The invention also includes therapeutic methods for treating cancers by administering to cancers patients therapeutically effective amounts of demethylating agents.

The present invention concerns pharmaceutical compositions comprising compounds with general formula I or poly-alkyl-bis-maltolic molecules and in particular derivatives of [(3-hydroxy-4-pyron-2-yl)methyl]-amine in combination with DNA demethylating agents as anti-neoplastic drugs. In particular, for the preparation of a medicament for the treatment of neoplastic pathologies.

The present invention relates to an improved process for O-demethylating methoxy substituted morphinan-6-one derivatives using AlCl3 as a demethylating agent in a reaction-inert solvent having a water content ranging from 0.1% wt to 0.8% wt. 10

Disclosed is the non-therapeutic use, as a DNA-demethylating agent, of at least one organometallic compound including an iron atom bound to two terpyridine groups. Further disclosed are method related to applying such agent as medicine.

Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting "personalized medicine" treatments.